Tags

Type your tag names separated by a space and hit enter

[Pneumococcal vaccination in adults].
Ned Tijdschr Geneeskd. 2003 Mar 08; 147(10):437-41.NT

Abstract

Pneumococcal pneumonia and bacteraemia are an important cause of morbidity and mortality, especially in a number of risk groups. On the basis of data from available literature, there is no convincing evidence that vaccination of such risk groups, including all people over 65, with a polyvalent vaccine of pneumococcal capsular polysaccharides in addition to influenza vaccination offers any additional protection against the risk of acquiring pneumococcal pneumonia. There is adequate evidence that pneumococcal vaccination does protect against invasive infections and that in this respect vaccination of all elderly persons could be cost-effective. However, there are insufficient data on whether pneumococcal vaccination provides additional protection against invasive infections in people already receiving influenza vaccination. Therefore a well-considered assessment of the cost-effectiveness of applying such a strategy in the Netherlands is not yet possible. Vaccination of (imminent) immuno-compromised persons is only effective and of value if an adequate antibody response can be expected. There is as yet no proven advantage of vaccination with a conjugate vaccine in adults.

Authors+Show Affiliations

Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Longziekten, Postbus 22.660, 1100 DD Amsterdam. r.e.jonkers@amc.uva.nlNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

dut

PubMed ID

12666513

Citation

Jonkers, R E., and W G. Boersma. "[Pneumococcal Vaccination in Adults]." Nederlands Tijdschrift Voor Geneeskunde, vol. 147, no. 10, 2003, pp. 437-41.
Jonkers RE, Boersma WG. [Pneumococcal vaccination in adults]. Ned Tijdschr Geneeskd. 2003;147(10):437-41.
Jonkers, R. E., & Boersma, W. G. (2003). [Pneumococcal vaccination in adults]. Nederlands Tijdschrift Voor Geneeskunde, 147(10), 437-41.
Jonkers RE, Boersma WG. [Pneumococcal Vaccination in Adults]. Ned Tijdschr Geneeskd. 2003 Mar 8;147(10):437-41. PubMed PMID: 12666513.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pneumococcal vaccination in adults]. AU - Jonkers,R E, AU - Boersma,W G, PY - 2003/4/2/pubmed PY - 2003/4/30/medline PY - 2003/4/2/entrez SP - 437 EP - 41 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 147 IS - 10 N2 - Pneumococcal pneumonia and bacteraemia are an important cause of morbidity and mortality, especially in a number of risk groups. On the basis of data from available literature, there is no convincing evidence that vaccination of such risk groups, including all people over 65, with a polyvalent vaccine of pneumococcal capsular polysaccharides in addition to influenza vaccination offers any additional protection against the risk of acquiring pneumococcal pneumonia. There is adequate evidence that pneumococcal vaccination does protect against invasive infections and that in this respect vaccination of all elderly persons could be cost-effective. However, there are insufficient data on whether pneumococcal vaccination provides additional protection against invasive infections in people already receiving influenza vaccination. Therefore a well-considered assessment of the cost-effectiveness of applying such a strategy in the Netherlands is not yet possible. Vaccination of (imminent) immuno-compromised persons is only effective and of value if an adequate antibody response can be expected. There is as yet no proven advantage of vaccination with a conjugate vaccine in adults. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/12666513/[Pneumococcal_vaccination_in_adults]_ DB - PRIME DP - Unbound Medicine ER -